1 Precision medicine for pandemics: stratification of COVID-19 molecular 2 phenotypes defined by topological analysis of global blood gene expression.

3

Rebekah Penrice-Randal^{1,2}, Fabio Strazzeri¹, Benoit Ernst³, Brice Van Eeckhout⁴, 4 Julien Guiot³, Anna Julie Peired⁵, Cosimo Nardi⁵, Erika Parkinson¹, Monique Henket 5 ³, Alicia Staderoli ³, Elora Guglielmi ³, Anne-Françoise Dive ³, Laurie Giltay ³, Sara 6 7 Tomassetti ⁶, Rebecca Baker ⁷, Kit Howard ⁷, Catherine Hartley ², Tessa Prince ², Thomas Kleyntssens⁴, Tommaso Manciulli⁸, Ratko Djukanovic^{9,10}, Tristan Clark^{9,10}, 8 9 Diana Baralle^{10,11}, Scott S Wagers¹², Xiaodan Xing¹³, Yang Nan¹³, Shiyi Wang¹³, Simon Walsh¹⁴, Guang Yang¹³, Paul J Skipp^{1,15}, Julian A Hiscox^{2,16,17}, James P R 10 11 Schofield ¹. 12 13 14 Affiliations: ¹TopMD Precision Medicine Ltd, Southampton, United Kingdom 15 16 ²Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, 17 Liverpool, UK. 18 ³Department of Respiratory Medicine, University Hospital of Liège, Liège, Belgium. 19 20 ⁴Comunicare Solutions, Liège, Belgium. 21 22 ⁵Department of Experimental and Clinical Biomedical Sciences "Mario Serio", 23 University of Florence, Viale Morgagni 50, 50134 Florence, Italy. 24 25 ⁶Department of Clinical and Experimental Medicine, Caregoi University Hospital, Largo Brambilla 3, 50134 Florence, IT 26 27 ⁷Clinical Data Interchange Standards Consortium (CDISC), Austin, TX, United States 28 29 of America 30 ⁸Department of Experimental and Clinical Medicine, University of Florence, Florence,

31

32

Italy. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

| 33 | |
|----|--|
| 34 | ⁹ Clinical and Experimental Sciences, Faculty of Medicine, University of |
| 35 | Southampton, Southampton, United Kingdom |
| 36 | |
| 37 | ¹⁰ National Institute for Health Research Southampton Biomedical Research Centre, |
| 38 | Southampton, United Kingdom |
| 39 | |
| 40 | ¹¹ School of Human Development and Health, Faculty of Medicine, University of |
| 41 | Southampton, Southampton, United Kingdom |
| 42 | |
| 43 | ¹² BioSci Consulting, Maasmechelen, Belgium |
| 44 | |
| 45 | ¹³ Department of Bioengineering and Imperial-X, Imperial College London |
| 46 | |
| 47 | ¹⁴ National Heart and Lung Institute, Imperial College London |
| 48 | |
| 49 | ¹⁵ School of Biological Sciences, University of Southampton, Southampton, UK |
| 50 | |
| 51 | ¹⁶ NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, |
| 52 | Liverpool, UK. |
| 53 | |
| 54 | ¹⁷ A*STAR Infectious Diseases Laboratories (A*STAR ID Labs), Agency for Science, |
| 55 | Technology and Research (A*STAR), Singapore. |
| 56 | |

57 Abstract:

Precision medicine offers a promising avenue for better therapeutic responses to 58 59 pandemics such as COVID-19. This study leverages independent patient cohorts in Florence and Liège gathered under the umbrella of the DRAGON consortium for the 60 stratification of molecular phenotypes associated with COVID-19 using topological 61 62 analysis of global blood gene expression. Whole blood from 173 patients was collected and RNA was sequenced on the Novaseg platform. Molecular phenotypes were 63 64 defined through topological analysis of gene expression relative to the biological 65 network using the TopMD algorithm. The two cohorts from Florence and Liège allowed 66 for independent validation of the findings in this study. Clustering of the topological maps of differential pathway activation revealed three distinct molecular phenotypes 67 of COVID-19 in the Florence patient cohort, which were also observed in the Liège 68 69 cohort.

70

Cluster 1 was characterised by high activation of pathways associated with ESC pluripotency, NRF2, and TGF-β receptor signalling. Cluster 2 displayed high activation of pathways including focal adhesion-PI3K-Akt-mTOR signalling and type I interferon induction and signalling, while Cluster 3 exhibited low IRF7-related pathway activation. TopMD was also used with the Drug-Gene Interaction Database (DGIdb), revealing pharmaceutical interventions targeting mechanisms across multiple phenotypes and individuals.

78

The data illustrates the utility of molecular phenotyping from topological analysis of blood gene expression, and holds promise for informing personalised therapeutic strategies not only for COVID-19 but also for Disease X. Its potential transferability across multiple diseases highlights the value in pandemic response efforts, offering insights before large-scale clinical studies are initiated.

- 84
- 85

86 Introduction:

87

The ongoing challenges of COVID-19, triggered by the emergence of SARS-CoV-2, necessitate a detailed understanding of disease heterogeneity. Despite extensive research characterising the host response to SARS-CoV-2 through pre-clinical (1, 2), and clinical (3-6) functional genomic data, there have been limited approaches that have used data from and encompassed the range of symptom severity, disease heterogeneity and delivered personalised medicine.

94

Examination of gene expression patterns in blood has been used in previous studies 95 to identify molecular phenotypes associated with different disease profiles in several 96 97 emerging viral infections including Ebola virus (EBOV) (7) and SARS-CoV-2 (1, 2, 4, 98 5), as well as more endemic infections such as influenza virus (8). Medical 99 countermeasures focus on either reducing viral load through anti-virals. These target 100 viral biology or modulate the host response to infection to reduce segualae such as 101 inflammation. For many viruses there is a clear correlation between viral load, disease 102 severity and outcome (survival/death). This is best typified by the Ebola virus where 103 low viral loads correlate with survival and high viral loads correlate with death (9). For SARS-CoV-2 this correlation is less obvious. In animal models of disease, such as the 104 105 ferret, viral load was correlated with symptomology (10); in humans, there is less data 106 to support an association between viral load and disease. However, studies have 107 shown that severe COVID-19 is associated with dysregulated immune pathology in 108 organs such as the lungs and the respiratory tract (3, 11).

109

With any emerging viral pathogen, direct acting antivirals take time to develop and trial. Identifying therapeutics that can modulate the host response to reduce symptomology remain a priority. Being able to rapidly characterise aberrations in host pathways that lead to disease and marrying this with therapeutics on the FDA approved list will enhance pandemic preparedness and rapid response. Therefore, a deeper understanding of the host response can be used to guide the selection of host directed medication countermeasures.

- 117
- 118
- 119

120 The field of digital health and precision medicine is rapidly evolving, with emerging 121 technologies and initiatives aimed at integrating diverse datasets to inform clinical decision-making. In this study we offer a novel way to analyse complex data collected 122 123 by the DRAGON international consortium which enables rapid identification of targets 124 for treatment by novel and/or re-purposed drugs. Within DRAGON, efforts have been 125 made to harmonise data in digital healthcare, proposing guidelines for the integration of clinical data from various modalities. (12). Additionally, an online platform has been 126 127 developed to host validated COVID-19 predictive models, facilitating their utilisation 128 by clinicians in real-time decision-making (13). However, challenges persist, as 129 evidenced by the limited success of outcome prediction models for COVID-19 patients 130 based on demographic and comorbidity data, which highlights the need for more 131 sophisticated approaches (14).

132

133 While omics data has been instrumental in advancing our understanding of SARS-134 CoV-2 and COVID-19, its integration into digital health platforms for clinical decision-135 making remains limited (15-17). Traditional molecular phenotyping approaches often 136 provide only shallow insights. In previous work, using topological analysis, we 137 demonstrated how gene expression data derived from whole blood at the time of 138 admission could predict ICU admission (5). However, the current study analysed the 139 blood transcriptomes of patients with COVID-19 as part of the DRAGON-EU consortium and used TopMD, an algorithm that considers all available data across a 140 141 landscape of pathways, to characterize molecular phenotypes of COVID-19 patients 142 admitted to hospital. Pathways were identified that correlated with clinical disease in 143 the patient cohort. TopMD mapped pathways onto a database containing information 144 on FDA approved drugs and their known gene and pathway interactions to generate 145 a list of potential therapeutics for modulating severe COVID-19. The ability to rapidly identify and therapeutically modulate host pathways responsible for disease with pre-146 147 existing medical countermeasures will be important in the emergence of novel 148 diseases and future pandemics.

149

This study describes an analysis of the blood transcriptomes of patients with COVID-151 19 admitted to hospital in Liège and Florence between February and July 2021, as 152 part of the DRAGON-EU consortium. Alongside collecting blood samples, 153 demographic and clinical observations were recorded; additionally, CT scan data were 154 obtained for a subset of these patients. We applied an unsupervised approach, in which we characterised the molecular phenotypes of patients within this cohort. We 155 have previously reported the development of a gene signature in patients with COVID-156 19, predictive of admission to ICU (5). This predictive signature revealed the activation 157 158 of pathways regulating epidermal growth factor receptor (EGFR) signalling, peroxisome proliferator-activated receptor alpha (PPAR- α) signalling and transforming 159 160 growth factor beta (TGF-β) signalling. The observed molecular phenotype aligns with the mechanisms implicated in pulmonary fibrosis, which is also associated with 161 162 increased severity of disease (18-20).

164 **Methods:**

165

166 Study population and sample collection and ethics

167 Blood samples were obtained from 132 patients severe enough to require admission because of COVID-19 at Careggi University Hospital, Florence, Italy, and 41 from a 168 169 pre-defined, separate patient cohort in Liège, between February and July 2021. All 170 patients tested positive nasopharyngeal swab PCR for SARS-CoV-2 infection. Blood 171 samples were collected on Day 0 of hospital admission. The protocol was approved 172 by the ethics committee of the University Hospital of Liège (reference number 2021/89) 173 and the ethics committee of the UNIFI (#18085/OSS). Informed consent was obtained 174 for every participant.

175

176 Ethical Approval statement

The work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. All procedures were performed in compliance with relevant laws and institutional guidelines and have been approved by the appropriate institutional committees. Informed consent was obtained for every participant.

182 Clinical data were collected from the patients' electronic medical records by the 183 investigators, and included age, sex, BMI, comorbid conditions etc. The data were 184 then assembled using the Study Data Tabulation Model (SDTM) data format 185 developed by the Clinical Data Interchange Standards Consortium (CDISC).

186 Chest CT analysis

187 Out of the 173 patients with RNA sequencing data, chest CT data was obtained from 188 109 patients using a 128-detector multislice Spiral Computed Tomography (MSCT) 189 (Somatom Definition AS, Siemens Healthcare, Erlangen, Germany) applying the 190 following parameters: current × exposure time 150 mAs, tube voltage 100 kV, rotation 191 time 0.3 s, pitch 1.2 mm, pixel size 0.465 mm, beam collimation 128 × 0.6 mm, both slice thickness and reconstruction 1 mm, and reconstruction kernel Bf70 very sharp. 192 193 Axial images were carried out from lung apexes to bases with patient at full inspiration 194 mand breath hold. Post-processing, 1-mm-thick sections were reconstructed on 195 coronal and sagittal planes oriented on the tracheal plane. Intravenous contrast 196 medium was not administered. Chest CT images were displayed on a 24-inch medical 197 monitor with a 3-megapixel Barco display (Barco, Kortrijk, Belgium) and 2048 x 1536 198 resolution. The software programs originally implemented to MSCT were used for 199 image assessment. Images of each patient were evaluated for scan quality 200 considering inspiratory level and motion artifacts. Data pulled out from CT 201 examinations included CO-RADS, chest CT score, dominant pattern, and 202 typical/atypical findings. Specifically:

203 **CO-RADS**

- 204 CO-RADS score based on COVID-19 lung involvement and variable from 1 to 205 5, with higher values reflecting a greater level of suspicion of COVID-19 206 infection with lung involvement. CO-RADS is a score used to diagnose COVID-207 19 and does not inevitably reproduce the severity of lung alterations. Low scores corresponded to CT examinations with alterations less likely related to 208 209 COVID-19 infection. The 5-score CO-RADS scale is as follows: 1: very low level of suspicion; 2: low level of suspicion; 3: equivocal findings; 4: high level of 210 211 suspicion; 5: very high level of suspicion.
- 212 Chest CT score for lobe involvement
- 213 Ranging from 0 to 5, namely 0: 0%; 1: <5%; 2: 5-25%; 3: 26-50%; 4: 51-75%;
 214 5: >75%.

215 **Dominant chest CT pattern**

- 216 Evaluated in relation to the prevalent alterations among ground-glass opacities,
- 217 consolidations, ground-glass opacities together with consolidations, crazy-218 paving, and reverse halo, as defined by the Fleischner Society.
- 219 **Dominant chest CT distribution**
- 220 Lower lobes, upper lobes, peripheral, bronchocentric, dorsal, or diffuse.

221 Additional COVID-19 related findings

- 222 Represented by pleural thickening, vascular enlargement, subpleural sign, halo
- sign air, bubble sign, perilobular pattern, and subpleural sparing.

Additional findings not typical for COVID-19

225 Represented by pleural effusion, pericardial effusion, lymphadenopathy,

cavitation, tree-in-bud, discrete small nodules, isolated lobar/segmental
 consolidation, atelectasis, and smooth interlobular septal thickening.

228 **RNA extraction**

229 Total RNA was extracted from PAXgene BRT using the PAXgene Blood RNA Kit 230 (PreAnalytix), according to the manufacturer's protocol. Extracted RNA was stored at 231 -80°C until further use. Following the manufacturer's protocols, total RNA was used 232 as input material into the QIAseq FastSelect-rRNA/Globin Kit (Qiagen) protocol to 233 remove cytoplasmic and mitochondrial rRNA and globin mRNA with a fragmentation 234 time of 7 or 15 minutes. Subsequently the NEBNext[®] Ultra[™] II Directional RNA Library 235 Prep Kit for Illumina[®] (New England Biolabs) was used to generate the RNA libraries, 236 followed by 11 or 13 cycles of amplification and purification using AMPure XP beads. 237 Each library was quantified using Qubit and the size distribution assessed using the 238 Agilent 2100 Bioanalyser and the final libraries were pooled in equimolar ratios. 239 Libraries were sequenced using 150 bp paired-end reads on an Illumina[®] NovaSeq 6000 (Illumina[®], San Diego, USA). 240

241

242 **Bioinformatics**

Raw fastq files were trimmed using fastp (21). Trimmed paired end sequencing reads
were inputted into salmon (v1.5.2) using the -I A –validateMappings –SeqBias –gcBias
parameters (22). Quant files generated with salmon were imported into RStudio (4.1.1)
using tximport to infer gene expression (23). The edgeR package (3.34.1) was used
to normalise and scale sequencing libraries (24). Sequencing reads are available
under BioProject ID: PRJNA1085259 on Short Read Archive (SRA).

249

250 Molecular phenotypes mapped by topological analysis

251 Molecular phenotypes were mapped by topological analysis, using TopMD to measure 252 the shape of global gene expression relative to the biological network (TopMD Patent 253 number GB202306368D0). TopMD works in the following way: The biological network 254 used was an interaction network retrieved from the STRING database (25). The gene 255 nodes of the biological network were assigned vertices according to the measured 256 gene expression. The topological shape, or landscape, of this network is then measured by TopMD's algorithm, clustering differential gene expression hotspots, 257 258 corresponding to modulated gene pathways. These pathways have 'volume'

comprising the sum of squared differential gene expression of clustered genes, where
the most differentially activated pathways have the highest pathway topological
volumes. The molecular phenotype is defined as the global profile of volumes of
differential pathway activation.

263



264 265

266 Drug interactions mapped by topological analysis

267

268 Due to the power of TopMD analysis we can group genes depending on their 269 expression values, this means that for each average expression of any cluster of 270 samples, and even on individual samples, we can extrapolate a tailored gene set of 271 activated gene-groups for such expression. These gene-groups can be then compared to other gene sets, as in GSEA, as well against genes activated by specific drugs. To 272 273 do so, we utilised the Drug-Gene Interaction Database (26) obtained using genes or gene products that are known or predicted to interact with drugs, and compared via a 274 275 binomial distribution test, the probability that an overlap between such genes and a 276 TopMD gene-group was random. This was measured using a p-value associated with 277 binomial statistic, together with other measures, such as the (Bonferroni) adjusted p-278 value, a TopMD volume (combining volume of the shape with the statistical 279 significance of the drug-group combination) as well as an activation value, sum of the 280 Log2 fold-change of those genes belonging to both the drug associated gene set and 281 the TopMD group.

282

283 Regression

Regression analysis was carried out using a Logistic regression model with thefollowing optimisation problem:

286

$$\min_w C \sum_{i=1}^n s_i \left(-y_i \log(\hat{p}(X_i)) - (1-y_i) \log(1-\hat{p}(X_i)) \right) + r(w)$$

287

Where X is the **pathway matrix** and y is the vector of the classification, 0 when the ith sample is in the class considered and 1 otherwise. We considered a regularisation parameter C value of 1. For the penalisation term r(w) for the regression weights w, we considered an ElasticNet penalisation with the **I1 ratio** parameter value of 0.5

293
$$\frac{1-\rho}{2}w^Tw + \rho \|w\|_1$$

294 The probability the i-th sample with **pathways values** equal to Xi is then:

$$\hat{p}(X_i)=\operatorname{expit}(X_iw+w_0)=rac{1}{1+\exp(-X_iw-w_0)}$$

295

296 With w0 the intercept. The python module used was **scikit-learn (version 1.4.1)** and

the algorithm used LogisticRegression function in the linear_model submodule.

298

299 We performed a 70/30 balanced split in the data from both cohorts separately (?), with 300 10 different splits. For each class we performed the regression based on a different 301 number of pathways, from 1 to 20, ranked in each split separately by their pathway 302 volume. For each regression model so obtained an average score of both training and 303 test splits was carried and the best model was selected using a max-min approach, 304 that is the best model was the one with highest value min(AUC on Train, AUC on Test), 305 to avoid selecting models which were ill-performing on train splits, but instead for 306 random effects very well on test splits.

307

308

309 Patient Clustering

Pathway volumes were plotted on a PCA using PCAtools (v2.14.0), revealing 3 distinct
 clusters, confirmed by K-means clustering, based on pathway activation against
 healthy controls. The top ten (10%) of the PCA loadings were then extracted to identify

- 313 which pathways were driving cluster separation. To analyse differentially activated
- 314 pathways between patient clusters, we calculated the average volume, across each
- 315 cluster, of each pathway relative to the average of all the COVID-19 patients.
- 316

317 Logistic Regression Receiver Operating Characteristic (LRROC) analysis using

- 318 patient clusters derived from the patient pathway volume matrix.
- 319

The area under the ROC curve (AUC) is a measure of the model's ability to distinguish 320 321 between classes. A higher AUC indicates better discrimination and, consequently, 322 stronger patient clusters. LRROC for Florence Patients: LRROC analysis was 323 performed exclusively for Florence patients. The patient pathway volume matrix for Florence patients was utilized to train the LRROC model. The output consisted of a 324 325 Receiver Operating Characteristic (ROC) curve, which depicted the classification 326 performance of patient clusters based on pathway volume. To evaluate the model's 327 generalization capability, the dataset was split into training and testing sets, and 328 separate ROC curves were generated for each.

329

Validation of clusters for Liège Patients: The LRROC model trained on Florence
 patients was validated on Liège patients' data. Using the trained model, an additional
 ROC curve was generated solely for Liège patients to assess the model's performance
 in classifying Liège patient clusters based on pathway volume.

- 334
- 335

336 Integration into digital health platform

337 As a proof of concept, transcriptomics data and TopMD analysis were integrated with 338 a healthcare platform ran by Comunicare (27). This was to highlight the possibilities of 339 integrating omics data into healthcare and digital health platforms. Similar regression analysis of COVID-19 blood transcriptomes, predicting ICU admission, performed 340 within the DRAGON scope (5) generated a linear model which is currently used to 341 342 generate prediction scores between 0 and 1, using TopMD analysis of each sample 343 submitted. In this way we can present TopMD analysis of individual samples compared to a healthy baseline, which includes pathway activation information, together with a 344 345 similarity score to the ICU admitted average patient we extracted from previous data.

346 **Results**:

347

To investigate whether blood transcriptomic analysis coupled with a machine learning 348 approach underpinned by TopMD could be integrated with clinical data, RNA 349 350 sequencing was performed on peripheral blood obtained from 173 patients from Liège 351 (n=41) and Florence (n=132) gathered under the auspices of the DRAGON 352 consortium. A summary of the patient characteristics is described in Supplementary 353 Table 1. Within this cohort ten patients had fatal disease. As no outcome variables 354 within this cohort had power, an unsupervised approach was undertaken. Out of the 173 patients, 109 patients had matched CT data scored by clinicians. The data is 355 summarised in Supplementary Table 2. The majority of patients had a CORADS score 356 of high and very high, where 26% was equivocal, 4.6% low and 2.8% very low. The 357 CORADS score stands for "COVID-19 Reporting and Data System," which is a 358 359 classification system used in radiology to assess the likelihood of COVID-19 infection based on chest imaging findings, typically on computed tomography (CT) scans. The 360 361 score categorizes imaging findings into different levels of suspicion for COVID-19. 362 ranging from very low to very high.

363

364 Table 1: Characteristics of 132 patients from Florence included in the study,

365 including lab results at admission.

| Characteristic | Ν | N = 132 ¹ |
|--------------------------|-----|----------------------|
| Died | 132 | |
| Ν | | 127 (96%) |
| Υ | | 5 (3.8%) |
| Age | 132 | 60 (50, 68) |
| Sex | 132 | |
| F | | 40 (30%) |
| Μ | | 92 (70%) |
| Non-invasive ventilation | 132 | |

| Ν | | 123 (93%) |
|--|-----|-----------|
| γ | | 9 (6.8%) |
| Continuous positive airway pressure | 132 | |
| Ν | | 129 (98%) |
| Y | | 3 (2.3%) |
| Tracheostomy | 132 | |
| Ν | | 131 (99%) |
| Y | | 1 (0.8%) |
| High flow nasal cannula oxygen therapy | 132 | |
| Ν | | 105 (80%) |
| Y | | 27 (20%) |
| Hypertension | 132 | |
| Ν | | 77 (58%) |
| Y | | 55 (42%) |
| Malnutrition | 132 | |
| Ν | | 131 (99%) |
| Y | | 1 (0.8%) |
| Cardiovascular disease | 132 | |
| Ν | | 119 (90%) |
| Y | | 13 (9.8%) |
| Respiratory disease | 132 | |
| Ν | | 118 (89%) |
| Y | | 14 (11%) |
| | | |

| Cancer | 132 | |
|----------------------------------|-----|----------------------|
| Ν | | 118 (89%) |
| Y | | 14 (11%) |
| Chronic kidney disease | 132 | |
| Ν | | 130 (98%) |
| Y | | 2 (1.5%) |
| Chronic hepatitis | 132 | |
| Ν | | 130 (98%) |
| Y | | 2 (1.5%) |
| Cerebrovascular disease | 132 | |
| Ν | | 125 (95%) |
| Y | | 7 (5.3%) |
| Chronic hematologic disease | 132 | |
| Ν | | 129 (98%) |
| Y | | 3 (2.3%) |
| Diastolic blood pressure (mmHg) | 132 | 79 (70, 85) |
| Heart rate (BPM) | 130 | 80 (75, 89) |
| Systolic blood pressure (mmHg) | 132 | 125 (115, 140) |
| Temperature (°C) | 131 | 36.50 (36.00, 37.20) |
| Weight (kg) | 128 | 78 (70, 89) |
| Height (cm) | 126 | 170 (165, 175) |
| Alanine aminotransferase (U/L) | 128 | 27 (17, 39) |
| Aspartate aminotransferase (U/L) | 64 | 31 (24, 46) |

| Bilirubin (mg/dL) | 128 | 0.50 (0.30, 0.60) |
|--|-----|----------------------|
| Calcium (mg/dL) | 96 | 4.50 (4.34, 4.63) |
| Creatinine (mg/dL) | 130 | 0.83 (0.73, 0.95) |
| D-dimer (ng/mL) | 91 | 728 (429, 1,091) |
| Direct bilirubin (mg/dL) | 44 | 0.25 (0.17, 0.29) |
| Fibrinogen (mg/dL) | 117 | 572 (446, 654) |
| Fraction of inspired oxygen (%) | 127 | 28 (21, 36) |
| Hematocrit (%) | 132 | 42.7 (39.7, 45.8) |
| Lactate dehydrogenase (U/L) | 118 | 297 (247, 359) |
| Lactic acid (mg/dL) | 102 | 9.0 (7.0, 11.9) |
| Leukocytes (10 ⁹ /L) | 132 | 6.2 (4.6, 7.7) |
| Lymphocytes (10 ⁹ /L) | 129 | 0.90 (0.68, 1.25) |
| Neutrophils (10 ⁹ /L) | 129 | 4.67 (3.08, 6.16) |
| Oxygen saturation (%) | 109 | 96.10 (94.20, 97.70) |
| Partial pressure oxygen (mmHg) | 131 | 74 (65, 87) |
| Partial pressure carbon dioxide (mmHg) | 127 | 36.2 (34.0, 39.0) |
| Platelets (10 ⁹ /L) | 132 | 196 (156, 255) |
| Potassium (mmol/L) | 128 | 3.85 (3.50, 4.10) |
| Procalcitonin (ug/L) | 126 | 0.09 (0.06, 0.15) |
| Prothrombin time (seconds) | 127 | 13.00 (12.30, 13.70) |
| Sodium (mmol/L) | 129 | 137 (135, 140) |
| Urea nitrogen (g/L) | 64 | 30 (30, 50) |
| ¹ n (%); Median (IQR) | | |

367 Patients form 3 clusters based on their pathway activation

368

369 The RNA sequencing data was used to derive gene expression data (mRNA identification and abundance) which was calculated using Salmon inferred with 370 371 Tximport in R, where values were converted into log2 counts per million (cpm). TopMD was then employed to calculate the activation of pathways. To identify differences in 372 373 pathway activation across the cohort, activation data was plotted on a PCA which revealed three distinct clusters of patients (Figure 1). The relationship between clinical 374 375 observations, demographics and CT scan data in each cluster was explored, and the 376 significant differences are reported in Table 3. Lactic acid was slightly higher in cluster 1 and 2 and lower in cluster 3. A higher proportion of respiratory disease was observed 377 378 in cluster 2 and the fraction of inspired oxygen was also higher in this cluster. Direct 379 bilirubin was also higher in cluster 2. The majority of those that died from COVID-19 380 were in cluster 2. CORADS scoring was unable to distinguish between the clusters at

a molecular level.





382

383 Figure 1:TopMD pathway volumes of each patient in the Florence cohort, calculated

384 from a healthy plotted as a PCA plot. The data reveals three distinct clusters based on

³⁸⁵ pathway activation determined by kmeans.

| 386 | Table 2: Patient characteristics that differ between the three clusters in the Florence |
|-----|---|
| 387 | cohort (p = <0.05). |

| Characteristic | Ν | 1 , N = 46 ¹ | 2 , N = 37 ¹ | 3 , N = 49 ¹ | p-value ² |
|---------------------------------------|-----|--------------------------------|--------------------------------|--------------------------------|----------------------|
| Lactic acid (mg/dL) | 102 | 10.0 (7.7, 13.0) | 10.0 (7.2, 12.0) | 8.0 (5.3, 9.7) | 0.008 |
| Fraction of inspired oxygen (%) | 127 | 28 (21, 36) | 32 (27, 40) | 28 (21, 29) | 0.019 |
| Died | 132 | | | | 0.032 |
| Ν | | 46 (100%) | 33 (89%) | 48 (98%) | |
| Y | | 0 (0%) | 4 (11%) | 1 (2.0%) | |
| Respiratory disease | 132 | | | | 0.042 |
| Ν | | 44 (96%) | 29 (78%) | 45 (92%) | |
| Y | | 2 (4.3%) | 8 (22%) | 4 (8.2%) | |
| Direct bilirubin (mg/dL) | 44 | 0.20 (0.17, 0.27) | 0.28 (0.24, 0.32) | 0.20 (0.17, 0.28) | 0.047 |

¹ n (%); Median (IQR)

² Fisher's exact test; Kruskal-Wallis rank sum test; Pearson's Chi-squared test

388

Molecular phenotype, Cluster 1, was characterised by high activation of pathways
associated with ESC pluripotency, NRF2, and TGF-β receptor signalling (Figure 2).
Molecular phenotype, Cluster 2 displayed high activation of pathways including focal
adhesion-PI3K-Akt-mTOR signalling and type I interferon induction and signalling,
while Cluster 3 exhibited low IRF7-related pathway activation.

LRROC analysis was conducted on models trained using 70% of patients from the Florence cohort, with test results evaluated on the remaining 30% of the Florence cohort. The area under the ROC curve (AUCROC) values were found to be 0.84, 0.85, and 0.72 for clusters Cluster 1, Cluster 2, and Cluster 3, respectively. Subsequently, these clusters were validated in the Liège cohort (Supplementary Figure 1), yielding AUCROC values of 0.76, 0.93, and 0.69 for Cluster 1, Cluster 2, and Cluster 3, respectively (Supplementary Figure 2).

- 402
- 403

404 **Potential drug candidates are identified for each cluster**

405 To identify potential drug candidates that modulate pathways identified in these

406 patient clusters, TopMD pathway activation was mapped onto the Drug-Gene

407 Interaction Database (Figure 3). This mapping revealed distinct drug targets for each

408 cluster, detailed in the supplementary table 4. This approach has a two-fold benefit:

409 informing potential clinical trials and informing underlying biological mechanisms

410 specific to each cluster. Interestingly, the pattern of pathway activation might also

411 provide insight into the potential benefits or drawbacks of specific therapies,

412 considering a drug's mechanism of action.

413 While all clusters shared targetable pathways led by genes such as ITGB2, GNAS,

414 and CXCR2, unique targets also emerged. Cluster 1 specifically identified IFNAR1,

415 TGFBR2, and CSF2RB, while cluster 2 added SERPING1 and TLN1. Notably, cluster

416 3 shared SERPING1 with cluster 2. These findings highlight both commonalities and

417 variations in potential therapeutic targets across the identified patient clusters.



Figure 2: The average pathway volume for each cluster was considered in a TopMD enrichment analysis against the average pathway activation for the whole cohort to identify differentially activated pathways. The enrichment analysis was filtered by adjusted P value, then the top pathways were plotted. The pathways are annotated with the gene that leads the identified pathway. The dots are coloured by adjusted p-value and the size represents the proportion of genes identified within that pathway from TopMD analysis.



Figure 3: TopMD enrichment analysis was mapped against the Drug-Gene Interaction Database, using a healthy baseline, revealing approved drugs that are known to target genes and their corresponding pathways. The top drug candidates are plotted based on 425 426 adjusted p-value and pathway volume.

427 Identification of pathways in fatal cases where intervention might 428 promote survival

429 Due to limited sample size, we focused on the unsupervised analysis; however, to 430 show utility of investigating pathway activity in individuals, pathway analysis in the 10 431 deceased patients from the Florence and Liège cohort were observed. Unsurprisingly. 432 these patients exhibited advanced age and high comorbidity rates (cardiovascular: 433 70%, respiratory: 50%, malnutrition: 40%, hypertension: 90%, cerebrovascular: 30%, chronic hepatitis: 40%). Interestingly, all 10 patients displayed a strong signal for 434 435 "nonalcoholic fatty liver disease" driven by the NDUFA9 and UQCRC2 genes (Figure 436 4).

437 Despite this shared pathway, individual analysis revealed heterogeneity among
438 deceased patients, highlighting the complex interplay between COVID-19,
439 comorbidities, and individual demographics on pathway activation.

Enrichment analysis identified potential therapeutic targets based on individual pathway activation. All patients displayed potential targets including CXCR2 (Figure 5). Additionally, specific druggable pathways were identified for some patients, including GNAS (multiple patients), ITGB2 (patients 2 & 6), CSF2RB (multiple patients), SERPING1 (5 patients), PIK3CD (patient 5), TGFBR2 (patient 9), and CUL4B (patient 10).

446



- 450 Figure 4: The top 6 pathways enriched in fatal cases within the Florence and Liège
- 451 cohort using a healthy baseline.



462

Figure 5: The top significant drug candidates and peak genes that could potentially
modulate the phenotype of the 10 fatal cases patients in the Florence and Liège
cohort.

468 **Discussion**:

Traditionally, molecular phenotyping requires data reduction and feature selection, 469 470 removing biological and technical 'noise', prior to pathway enrichment analysis, but 471 this leads to results which do not accurately represent the molecular phenotypes. 472 Topological analysis of global gene expression finds value in the low abundance 473 transcripts usually discarded as noise, as they represent the 'foothills' of largely 474 activated pathways in a comprehensive molecular landscape. By understanding the 475 molecular phenotype, it is possible to achieve more successful selection of 476 therapeutics, as medicines work at the molecular level as opposed to a clinical level 477 (28).

478

479 To redefine predictive models for patient outcomes and health trajectories, there is a 480 growing recognition of the importance of integrating complex datasets. This ranges 481 from biomarkers, clinical parameters to CT scans. For instance, a fully automated AI 482 framework was developed to extract features from chest CT scans for diagnosing 483 COVID-19. The model achieved 85.18% accuracy, enabling rapid and accurate 484 differentiation of COVID-19 from routine clinical conditions, facilitating timely 485 interventions and isolation procedures (29). Similarly, an AI-based analysis named 486 CACOVID-CT was implemented to automatically assess disease severity on chest CT 487 Retrospective analysis of 476 patients revealed that quantitative scans. 488 measurements, such as the percentage of affected lung area (% AA) and CT severity 489 score (CT-SS), correlated strongly with hospital length of stay, ICU admission, 490 mechanical ventilation, and in-hospital mortality. This tool proved effective in 491 identifying patients at higher risk of severe outcomes, facilitating patient management 492 and relieving the workload of radiologists (30).

493

494 Our study identified three distinct molecular phenotypes of COVID-19 molecular 495 through topological analysis of global blood gene expression. LRROC analysis 496 demonstrated strong discriminative power of the defined patient clusters tested in the 497 Florence and validated in the Liège cohort. This revealed insights into underlying 498 disease mechanisms, potentially guiding personalised therapeutic approaches.

499

500 The analysis using the TopMD algorithm assigned patients to three clusters. Some of 501 the clinical observations aligned with the defined clusters, including lactic acid elevation in cluster 1 and 2 compared to cluster 3. Elevated lactic acid is known to be
associated with disease severity and mortality (31). Similarly, cluster 2 showed a
higher proportion of respiratory disease and required a higher fraction of inspired
oxygen. Additionally, this cluster exhibited elevated direct bilirubin, another potential
indicator of disease severity (32). Notably, the majority of those that died from COVID19 were in cluster 2 (n=4), although the overall number of fatalities in this cohort was
small (n=5).

509

Interestingly, the CORADS scoring system used for chest X-ray/CT severity assessment, couldn't differentiate between the molecular clusters. This suggests different molecular mechanisms might underlie similar clinical presentations, which cannot be identified by CT scan. However, utilising higher resolution CT scan data, such as continuous scoring systems offered by tools like Thirona, might provide more granular insights compared to the categorical data used in this study (30).

516

517 Molecular differences were examined between each cluster by considering statistically 518 significant GSEA pathways with highest TopMD pathway volumes (Fig. 2). Cluster 1 519 displayed a reduction in pathways related to the renin-angiotensin system (RAS) and 520 bradykinin, implicated in COVID-19 pathogenesis (33). Additionally, an increase in focal adhesion pathways, possibly indicating cellular changes related to tissue repair 521 522 and remodelling. Activation of the complement cascade, led by SERPING1, indicates 523 involvement in the immune response to the virus. Furthermore, an increase in the 524 TGF- β pathway, which regulates inflammation and tissue repair was also identified. 525 Additionally, a high activation of pathways associated with ESC pluripotency, NRF2. 526 and TGF-β receptor signalling. The ESC pluripotency pathway is implicated in tissue 527 repair and regeneration, suggesting a potential compensatory response to tissue 528 damage caused by the virus. NRF2 pathway activation may indicate an antioxidant 529 response to counteract oxidative stress induced by viral infection (34). TGF-β receptor 530 signalling, known for its role in regulating inflammation and fibrosis, may contribute to 531 tissue remodelling and fibrosis observed in severe COVID-19 cases (35). Also, cluster 532 1 exhibits low activation of pathways related to extracellular vesicle-mediated 533 signalling and complement and coagulation cascades. The decrease in extracellular 534 vesicle-mediated signalling may reflect impaired intercellular communication, while the

535 low activation of complement and coagulation cascades suggests a possible536 dysregulated immune response and coagulopathy (36).

537

In cluster 2, high activation of pathways such as focal adhesion-PI3K-Akt-mTOR 538 539 signalling and type I interferon induction and signalling was observed, and has been 540 proposed as a potential therapeutic target in SARS-CoV-2 (37, 38) and MERS-CoV 541 (39). Focal adhesion pathway activation may indicate cellular responses to tissue 542 injury or viral invasion, while type I interferon induction and signalling reflect a strong 543 antiviral immune response (40). In contrast, cluster 3 shows opposite activity in IRF7-544 related pathways compared to 2. Additionally, vitamin D receptor activity was 545 observed, which has been implicated in modulating the immune response and may 546 play a role in COVID-19 severity (41-43). Notably, this cluster exhibited low activation 547 of pathways related to TGF- β receptor signalling, IL1R signalling, and LTF danger signal response. The reduced TGF- β receptor signalling suggests decreased fibrotic 548 549 response and tissue remodelling, while low IL1R signalling may indicate attenuated 550 inflammation (44). The activation of the LTF danger signal response pathway appears 551 to be diminished. Lactoferrin demonstrates antiviral capabilities against various 552 viruses, including coronaviruses (45). It can impede viral replication, disrupt viral 553 attachment and entry, and adjust host immune responses. Lactoferrin's 554 immunomodulatory attributes might aid in tempering excessive inflammation and 555 alleviating cytokine storms observed in severe cases of COVID-19 (46). The decreased activation of the LTF danger signal response pathway could potentially 556 557 contribute to a weakened interferon response (47).

558

559 The stratified molecular phenotypes were found to have different expected responses 560 to both medicines used, and medicines not yet used for COVID-19 (Fig. 3). In cluster 561 1, CSA or cyclosporine has been shown to be safe to use during COVID-19 for the intended use, however, a reduction in hyperinflammation was observed (48). This 562 563 warrants further investigation as highlighted by others (49). Interferon related therapies 564 that could modulate the pathway activation of cluster 1 were also identified, which have 565 been shown to have positive effects (50-52). Lifitegrast inhibits SARS-CoV-2 in vitro 566 (53, 54) By inhibiting TGF- β signalling, Luspatercept may help mitigate the excessive 567 inflammatory response and tissue damage seen in severe COVID-19 cases. Similarly,

568 Sargramostim has shown promise in a small study, but larger trials are needed to 569 confirm these findings (55).

570

571 Like, cluster 1, CSA was also identified as a potentially effective treatment for clusters 572 2 & 3. The mechanisms of actions of other medicines only matched the molecular 573 phenotype of cluster 2. Asenapine, an anti-pyschotic drug identified by others as a 574 potential drug candidate for COVID-19 (56, 57) Cinryze a human c1 esterase inhibitor 575 was also identified, these inhibitors have been shown to improve lung computed 576 tomography scores and increase blood eosinophils, which are indicators of disease 577 recovery, however, time to clinical improvement was not observed (58). Also, for 578 cluster 2, we identified Fluoxetine and other SSRIs such as fluvoxamine which has 579 previously been identified as having potential use for the treatment of COVID-19 and 580 long-COVID (59) Amisulpride was also identified in cluster 3.

581

582 To further evaluate the utility of the TopMD algorithm for precision medicine, 583 enrichment analysis was performed on individual data from the 10 fatal cases within 584 the Florence and Liège cohorts. This approach highlights pathway activation specific 585 to each patient, bypassing the need for a whole cohort for deconvolution. All 10 586 patients showed potential therapeutic targets based on pathway enrichment. CXCR2 587 and GNAS were commonly activated across patients (Figure 5), suggesting drugs such as Ibuprofen may be able to modulate some pathways associated with their 588 589 phenotype. For patients 2 and 6, ITGB2 emerged as one of the top druggable 590 pathways. Notably, Lifitegrast has shown to inhibit SARS-CoV-2 in vitro (53, 54). 591 Additionally, CSA or cyclosporine, was also identified, which was another compound 592 identified in the cluster analysis.

593

594 Multiple patients exhibited CSF2RB enrichment, indicating potential for Sargramostim, 595 a drug shown to reduce mortality and incubation in small COVID-19 study (55). 596 SERPING1 enrichment in 5 patients suggests various approved drugs for pathway 597 modulation, including antithrombin, human c1 esterase inhibitor and cinryze. Patient 598 specific findings were also observed. PIK3CD enrichment in patient 5 suggests 599 Sophoretin as a potentially modulator, with a meta-analysis showing quercetins 600 (including sophoretin), reduce LDH, hospitalisation risk and mortality (60). Patient 9 601 displayed TGFBR2 enrichment indicating luspatercept as a potential drug (identified

in the cluster analysis) as a potential candidate. Lastly, CUL4B enrichment in patient
10, suggests Thalidomide, Pomalidomide, Lenalidomide for pathway modulation.
While Lenalidomide, used to manage multiple myelomas, has been proposed as
protective against sever COVID-19 in a case report (61) a clinical trial showed no
benefit (62). Thalidomide, although showing no benefit itself (62), remains a subject of
discussion for its potential use in COVID-19 (63).

608

609 As a proof of concept, TopMD models were integrated into the Comunicare platform 610 (27), a tool developed and configured within the framework of the DRAGON project, 611 aimed at patient empowerment and providing disease management tooling for 612 clinicians and patients. This proof of concept also enables the analysis of clinical data 613 for clinicians in a dedicated dashboard to demonstrate the possibilities of 614 transcriptomics in digital health. As an example, we generated a model that predicts 615 ICU admission based on our previous work (5) as other outcome variables were too low in number. If a clinician has access to transcriptomic data, a csv file can be 616 617 uploaded to the dashboard and in return activated pathways are returned after running 618 analysis on the TopMD API. While the use of transcriptomics at the bedside is not 619 ready for deployment, we propose that it is a major advance to be able to demonstrate integration of this data into digital health platforms as the growth of precision medicine 620 621 continues.

622

This study identified three distinct molecular phenotypes in hospitalised COVID-19 patients, which were not associated with differences in CT scans and clinical observations. However, these molecular phenotypes match the mechanism of action of different medicines, providing the opportunity for biomarker-led stratified medicine. Topological analysis of global gene expression to define a patient's pathway activation map could be useful in future pandemics to aid in treatment decisions before clinical trials can be completed.

631 **Funding**:

TopMD, the University of Southampton, Imperial College London, CDISC, 632 Comunicare Solutions, University Hospital of Liège (CHU Liège), and the University of 633 634 Liverpool are members of the DRAGON consortium. The DRAGON project has 635 received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) 636 under grant agreement No 101005122. The JU receives support from the European Union's Horizon 2020 research and innovation program and EFPIA. This publication 637 638 reflects the author's view. Neither IMI nor the European Union, EFPIA or the DRAGON 639 consortium, are responsible for any use that may be made of the information contained 640 therein. JAH, TP, RPR and CH were supported by the US Food and Drug 641 Administration Medical Countermeasures Initiative (no 75F40120C00085) awarded to JAH and work was also supported by the MRC funded MR/Y004205/1 'The G2P2 642 643 virology consortium'. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. DB is funded by NIHR 644 and MRC. 645

646

647 **Acknowledgments**:

648 The authors wish to thank the study participants and the hospital staff for their 649 participation in this study.

650

651 **Contributions**:

RPR, FS: methodology, RPR, FS: visualisation, RPR, FS, BVE, TK: software, BE:
project administration, RPR, FS, JG, MH, AS, EG, AFD, LG, AJP, CN: investigation,
RPR, FS, JG, CH, TP, SW: formal analysis, JG, CN: clinical supervision, RPR, FS,
AJP, ST, RB, KH, XX, YN, SW: data curation, RPR, FS, EP, PS, JAH, JPS: writing original draft preparation, RPR, FB, BE, BE, JG, MH, AS, EG, AFD, LG, AJP, CN, ST,
RB, KH, CH, TP, RD, TC, DB, SW, XX, YN, SW, SW, GY, PJS, JAH, JPRS: writing review and editing, JPRS, JAH, PJS, GY, SW: funding acquisition

659

660 **Declarations:**

661 RPR is an employee at TopMD Precision Medicine Ltd. JPRS is a founding director,

662 CEO, employee, and shareholder in TopMD Precision Medicine Ltd. FS is a founding

director, CTO, employee, and shareholder in TopMD Precision Medicine Ltd. PS is a

- 664 founding director, employee, and shareholder in TopMD Precision Medicine Ltd. BVE
- 665 is CEO of Comunicare Solutions. TK is CTO of Comunicare Solutions.

666 **Data availability:**

667

668 Sequencing reads available under SRA bioproject: PRJNA1085259

669 **References:**

Clark JJ, Penrice-Randal R, Sharma P, Kipar A, Dong X, Pennington SH, et 670 1. 671 al. Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and 672 encephalitis in a mouse model of COVID-19. bioRxiv. 2023:2020.10.13.334532. 673 674 De Neck S, Penrice-Randal R, Clark JJ, Sharma P, Bentley EG, Kirby A, et al. 2. 675 The Stereotypic Response of the Pulmonary Vasculature to Respiratory Viral 676 Infections: Findings in Mouse Models of SARS-CoV-2, Influenza A and Gammaherpesvirus Infections. Viruses [Internet]. 2023; 15(8). 677 678 Dorward DA, Russell CD, Um IH, Elshani M, Armstrong SD, Penrice-Randal 3. 679 R, et al. Tissue-Specific Immunopathology in Fatal COVID-19. Am J Respir Crit Care Med. 2021;203(2):192-201. 680 681 Legebeke J, Lord J, Penrice-Randal R, Vallejo AF, Poole S, Brendish NJ, et 4. 682 al. Evaluating the Immune Response in Treatment-Naive Hospitalised Patients With 683 Influenza and COVID-19. Front Immunol. 2022;13:853265. 684 Penrice-Randal R, Dong X, Shapanis AG, Gardner A, Harding N, Legebeke J, 5. et al. Blood gene expression predicts intensive care unit admission in hospitalised 685 patients with COVID-19. Front Immunol. 2022;13:988685. 686 687 Russell CD, Valanciute A, Gachanja NN, Stephen J, Penrice-Randal R, 6. 688 Armstrong SD, et al. Tissue Proteomic Analysis Identifies Mechanisms and Stages 689 of Immunopathology in Fatal COVID-19. Am J Respir Cell Mol Biol. 2021. Liu X, Speranza E, Muñoz-Fontela C, Haldenby S, Rickett NY, Garcia-Dorival 690 7. 691 I, et al. Transcriptomic signatures differentiate survival from fatal outcomes in 692 humans infected with Ebola virus. Genome Biology. 2017;18(1):4. 693 McClain MT, Constantine FJ, Nicholson BP, Nichols M, Burke TW, Henao R, 8. 694 et al. A blood-based host gene expression assay for early detection of respiratory 695 viral infection: an index-cluster prospective cohort study. Lancet Infect Dis. 696 2021;21(3):396-404. 697 Carroll MW, Matthews DA, Hiscox JA, Elmore MJ, Pollakis G, Rambaut A, et 9. 698 al. Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West 699 Africa. Nature. 2015;524(7563):97-101. 700 Watson RJ, Tree J, Fotheringham SA, Hall Y, Dong X, Steeds K, et al. Dose-10. 701 Dependent Response to Infection with Ebola Virus in the Ferret Model and Evidence 702 of Viral Evolution in the Eye. Journal of virology. 2021;95(24):e0083321. 703 11. Russell CD, Valanciute A, Gachanja NN, Stephen J, Penrice-Randal R, 704 Armstrong SD, et al. Tissue proteomic analysis identifies mechanisms and stages of 705 immunopathology in fatal COVID-19. American journal of respiratory cell and 706 molecular biology. 2022;66(2):196-205. 707 Nan Y, Ser JD, Walsh S, Schönlieb C, Roberts M, Selby I, et al. Data 12. 708 harmonisation for information fusion in digital healthcare: A state-of-the-art 709 systematic review, meta-analysis and future research directions. Information Fusion. 710 2022;82:99-122. 711 Halilaj I, Chatterjee A, van Wijk Y, Wu G, van Eeckhout B, Oberije C, et al. 13. 712 Covid19Risk.ai: An Open Source Repository and Online Calculator of Prediction 713 Models for Early Diagnosis and Prognosis of Covid-19. BioMed. 2021;1(1):41-9. 714 Chatterjee A, Wu G, Primakov S, Oberije C, Woodruff H, Kubben P, et al. Can 14. 715 predicting COVID-19 mortality in a European cohort using only demographic and 716 comorbidity data surpass age-based prediction: An externally validated study. PLOS ONE. 2021;16(4):e0249920. 717

- T18
 T5. Cen X, Wang F, Huang X, Jovic D, Dubee F, Yang H, et al. Towards precision
 medicine: Omics approach for COVID-19. Biosaf Health. 2023;5(2):78-88.
- Teodori L, Osimani B, Isidoro C, Ramakrishna S. Mass versus personalized
 medicine against COVID-19 in the "system sciences" era. Cytometry Part A.
 2022;101(12):995-9.
- 17. Wang Z, He Y. Precision omics data integration and analysis with
 interoperable ontologies and their application for COVID-19 research. Briefings in
 Functional Genomics. 2021;20(4):235-48.
- 18. Venkataraman T, Coleman CM, Frieman MB. Overactive Epidermal Growth
 Factor Receptor Signaling Leads to Increased Fibrosis after Severe Acute
- 728 Respiratory Syndrome Coronavirus Infection. Journal of virology. 2017;91(12).
- 19. Venkataraman T, Frieman MB. The role of epidermal growth factor receptor
 (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis. Antiviral Res.
 2017;143:142-50.
- Vagapova ER, Lebedev TD, Prassolov VS. Viral fibrotic scoring and drug
 screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19
 fibrosis. Scientific Reports. 2021;11(1):11234.
- 735 21. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ 736 preprocessor. Bioinformatics. 2018;34(17):i884-i90.
- Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast
 and bias-aware quantification of transcript expression. Nature Methods.
- 739 2017;14(4):417-9.
- 23. Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq:
- transcript-level estimates improve gene-level inferences. F1000Res. 2015;4:1521.
- 742 24. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for
 743 differential expression analysis of digital gene expression data. Bioinformatics.
 744 2010;26(1):139-40.
- 745 25. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al.
 746 The STRING database in 2023: protein-protein association networks and functional
 747 enrichment analyses for any sequenced genome of interest. Nucleic Acids Res.
- 748 2023;51(D1):D638-d46.
- 749 26. Freshour SL, Kiwala S, Cotto KC, Coffman AC, McMichael JF, Song JJ, et al.
 750 Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open
- 751 crowdsource efforts. Nucleic Acids Res. 2021;49(D1):D1144-d51.
- 752 27. Duquenne JB, Corhay JL, Louis R, Van Cauwenberge H. [Feasibility and
- 753 effectiveness study of a simplified mobile self-education and self-monitoring
- application for patients with severe chronic obstructive pulmonary disease]. Rev MedLiege. 2022;77(2):110-7.
- 756 28. Farahani M, Niknam Z, Mohammadi Amirabad L, Amiri-Dashatan N, Koushki
- 757 M, Nemati M, et al. Molecular pathways involved in COVID-19 and potential
- 758 pathway-based therapeutic targets. Biomedicine & Pharmacotherapy.
- 759 2022;145:112420.
- 760 29. Guiot J, Vaidyanathan A, Deprez L, Zerka F, Danthine D, Frix A-N, et al.
- 761 Development and Validation of an Automated Radiomic CT Signature for Detecting
 762 COVID-19. Diagnostics. 2021;11(1):41.
- Guiot J, Maes N, Winandy M, Henket M, Ernst B, Thys M, et al. Automatized
 lung disease quantification in patients with COVID-19 as a predictive tool to assess
- 765 hospitalization severity. Frontiers in Medicine. 2022;9.

31. Carpenè G, Onorato D, Nocini R, Fortunato G, Rizk JG, Henry BM, et al. 766 767 Blood lactate concentration in COVID-19: a systematic literature review. Clin Chem 768 Lab Med. 2022;60(3):332-7. 769 Chen W, Liu H, Yang G, Wang W, Liu Q, Huang C, et al. Effect of Direct 32. 770 Bilirubin Level on Clinical Outcome and Prognoses in Severely/Critically III Patients With COVID-19. Front Med (Lausanne). 2022;9:843505. 771 772 Garvin MR, Alvarez C, Miller JI, Prates ET, Walker AM, Amos BK, et al. A 33. 773 mechanistic model and therapeutic interventions for COVID-19 involving a RAS-774 mediated bradykinin storm. Elife. 2020;9. 775 Lee C. Therapeutic Modulation of Virus-Induced Oxidative Stress via the Nrf2-34. 776 Dependent Antioxidative Pathway. Oxid Med Cell Longev. 2018;2018:6208067. 777 Chen J, Wu W, Wang W, Tang Y, Lan H-Y. Role of TGF-β Signaling in 35. 778 Coronavirus Disease 2019. Integrative Medicine in Nephrology and Andrology. 779 2022;9(1):9. Conway EM, Mackman N, Warren RQ, Wolberg AS, Mosnier LO, Campbell 780 36. 781 RA, et al. Understanding COVID-19-associated coagulopathy. Nat Rev Immunol. 782 2022;22(10):639-49. 783 Fattahi S, Khalifehzadeh-Esfahani Z, Mohammad-Rezaei M, Mafi S, Jafarinia 37. 784 M. PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy. 785 Immunol Res. 2022;70(3):269-75. Khezri MR, Varzandeh R, Ghasemnejad-Berenji M. The probable role and 786 38. 787 therapeutic potential of the PI3K/AKT signaling pathway in SARS-CoV-2 induced 788 coagulopathy. Cell Mol Biol Lett. 2022;27(1):6. 789 Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, et al. 39. 790 Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for 791 Middle East respiratory syndrome coronavirus infection as identified by temporal 792 kinome analysis. Antimicrob Agents Chemother. 2015;59(2):1088-99. 793 40. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: 794 causes and consequences of cytokine storm and immunopathology. Semin 795 Immunopathol. 2017;39(5):529-39. 796 Azmi A, Rismani M, Pourmontaseri H, Mirzaii E, Niknia S, Miladpour B. The 41. 797 role of vitamin D receptor and IL-6 in COVID-19. Mol Genet Genomic Med. 798 2023;11(7):e2172. 799 42. Hurst EA, Mellanby RJ, Handel I, Griffith DM, Rossi AG, Walsh TS, et al. 800 Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors: a 801 cross-sectional study. BMJ Open. 2021;11(10):e055435. 802 Evans RM, Lippman SM. Shining Light on the COVID-19 Pandemic: A 43. 803 Vitamin D Receptor Checkpoint in Defense of Unregulated Wound Healing. Cell 804 Metabolism. 2020;32(5):704-9. 805 Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-β signaling in fibrosis. 44. 806 Growth Factors. 2011;29(5):196-202. 807 45. Puddu P, Valenti P, Gessani S. Immunomodulatory effects of lactoferrin on antigen presenting cells. Biochimie. 2009;91(1):11-8. 808 809 Zimecki M, Actor JK, Kruzel ML. The potential for Lactoferrin to reduce SARS-46. 810 CoV-2 induced cytokine storm. Int Immunopharmacol. 2021;95:107571. 811 Actor JK, Hwang SA, Kruzel ML. Lactoferrin as a natural immune modulator. 47. 812 Curr Pharm Des. 2009;15(17):1956-73. 813 48. Blumberg EA, Noll JH, Tebas P, Fraietta JA, Frank I, Marshall A, et al. A 814 phase I trial of cyclosporine for hospitalized patients with COVID-19. JCI Insight. 815 2022;7(11).

49. Devaux CA, Melenotte C, Piercecchi-Marti MD, Delteil C, Raoult D. 816 817 Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19? Front Med (Lausanne). 2021:8:663708. 818 819 Kamyshnyi A, Koval H, Kobevko O, Buchynskyi M, Oksenych V, Kainov D, et 50. 820 al. Therapeutic Effectiveness of Interferon- α 2b against COVID-19 with Community-Acquired Pneumonia: The Ukrainian Experience. Int J Mol Sci. 2023;24(8). 821 822 Reis G, Moreira Silva EAS, Medeiros Silva DC, Thabane L, Campos VHS, 51. Ferreira TS, et al. Early Treatment with Pegylated Interferon Lambda for Covid-19. 823 824 New England Journal of Medicine. 2023;388(6):518-28. 825 Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. 52. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment 826 of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 827 828 trial. The Lancet Respiratory Medicine. 2021;9(2):196-206. Shen X-R, Geng R, Li Q, Chen Y, Li S-F, Wang Q, et al. ACE2-independent 829 53. 830 infection of T lymphocytes by SARS-CoV-2. Signal Transduction and Targeted 831 Therapy. 2022;7(1):83. 832 54. Day CJ, Bailly B, Guillon P, Dirr L, Jen FE, Spillings BL, et al. Multidisciplinary 833 Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike 834 Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions. mBio. 835 2021;12(2). 836 Paine R, Chasse R, Halstead ES, Nfonoyim J, Park DJ, Byun T, et al. Inhaled 55. 837 Sargramostim (Recombinant Human Granulocyte-Macrophage Colony-Stimulating 838 Factor) for COVID-19-Associated Acute Hypoxemia: Results of the Phase 2, 839 Randomized, Open-Label Trial (iLeukPulm). Mil Med. 2022;188(7-8):e2629-38. 840 Ku KB, Shin HJ, Kim HS, Kim BT, Kim SJ, Kim C. Repurposing Screens of 56. 841 FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2. J Microbiol Biotechnol. 842 2020;30(12):1843-53. 843 Rajput A, Thakur A, Rastogi A, Choudhury S, Kumar M. Computational 57. 844 identification of repurposed drugs against viruses causing epidemics and pandemics 845 via drug-target network analysis. Comput Biol Med. 2021;136:104677. 846 Mansour E, Palma AC, Ulaf RG, Ribeiro LC, Bernardes AF, Nunes TA, et al. 58. 847 Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-848 Kallikrein System in Severe COVID-19. Viruses. 2021;13(2). 849 Hashimoto K. Overview of the potential use of fluvoxamine for COVID-19 and 59. 850 long COVID. Discov Ment Health. 2023;3(1):9. 851 60. Ziaei S, Alimohammadi-Kamalabadi M, Hasani M, Malekahmadi M, Persad E, 852 Heshmati J. The effect of guercetin supplementation on clinical outcomes in COVID-853 19 patients: A systematic review and meta-analysis. Food Science & Nutrition. 854 2023;11(12):7504-14. 855 Al Sbihi A, Manasrah N, Sano D. Can Lenalidomide Protect against Severe 61. 856 COVID-19 Symptoms in Multiple Myeloma Patients? A Case Series and Review of 857 the Literature. Eur J Case Rep Intern Med. 2022;9(3):003216. 858 Amra B, Ashrafi F, Torki M, Hashemi M, Shirzadi M, Soltaninejad F, et al. 62. 859 Thalidomide for the Treatment of COVID-19 Pneumonia: A Randomized Controlled 860 Clinical Trial. Adv Biomed Res. 2023;12:14. 861 Sundaresan L, Giri S, Singh H, Chatterjee S. Repurposing of thalidomide and 63. 862 its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action. 863 Br J Clin Pharmacol. 2021;87(10):3835-50. 864